Login to Your Account



Vernalis Continues Rebound, Inks Potential $206M GSK Deal

By Jennifer Boggs


Friday, August 7, 2009
Though a regulatory hitch with migraine drug frovatriptan threatened to derail the company last year, Vernalis plc has turned its fortunes around in the last several months, closing a solid financing in May and now signing an early stage oncology collaboration with GlaxoSmithKline plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription